Biopharma and Leads - Pharma Rep Focus

Safety Risk Sinks Cargo Therapeutics’ Cancer Cell Therapy Prospect, Leading to 50% Staff Cut

MedCity News

JANUARY 30, 2025

The post Safety Risk Sinks Cargo Therapeutics Cancer Cell Therapy Prospect, Leading to 50% Staff Cut appeared first on MedCity News. Cargo is discontinuing the study and shifting focus to a different cell therapy on track to begin Phase 1 testing in mid-2025.

Prospecting

Prospecting Safety Leads Biopharma

Eli Lilly’s Zepbound Leads to Greater Weight Loss vs. Novo Nordisk Drug in Head-to-Head Test

MedCity News

DECEMBER 4, 2024

The post Eli Lilly’s Zepbound Leads to Greater Weight Loss vs. Novo Nordisk Drug in Head-to-Head Test appeared first on MedCity News. Eli Lilly obesity drug Zepbound led to 47% greater relative weight loss compared to Wegovy in a head-to-head clinical trial.

Leads

Leads Competition Medical Marketing

Going In Reverse Is Faster Way Forward for Crescent Bio’s Cancer Immunotherapy

MedCity News

OCTOBER 29, 2024

Crescent Biopharma is going public via a reverse merger with GlycoMimetics that will capitalize the combined company with $200 million.

Biopharma

Biopharma Leads Pharma

Rare Metabolic Disease That Leads to Childhood Obesity Gets Its First FDA-Approved Drug

MedCity News

MARCH 27, 2025

The once-daily pill is the first approved therapy for this rare disease, a leading cause of childhood obesity. The post Rare Metabolic Disease That Leads to Childhood Obesity Gets Its First FDA-Approved Drug appeared first on MedCity News.

Leads

Leads FDA Patients Biopharma

3 Reasons Why The Biopharma M&A Market Is Ready For Takeoff

MedCity News

AUGUST 21, 2023

Healthcare M&A deals are expected to pick up over the next few months, and one expert is predicting that the biopharma sector in particular will see especially robust activity.

Biopharma

Biopharma Marketing Healthcare Healthcare

Disappointing data lead Pfizer to drop heart drug acquired as part of $11B deal

MedCity News

AUGUST 4, 2022

billion acquisition of Array Biopharma in 2019. Pfizer is stopping work on a drug for a rare heart disease after an interim look at Phase 3 data indicated that the study was unlikely to succeed. The small molecule came to Pfizer’s drug pipeline as part of the $11.4

Biopharma

Biopharma Leads Pharma

An ocean of answers in a single cell — how proteomics can lead to better drugs

PharmaVoice

MARCH 21, 2024

New tools that allow researchers to separate single cells can help map the complex web of proteins that lead to disease, providing new targets for biopharma.

Leads

Leads Biopharma

Novo Nordisk, Eli Lilly lead industrywide sales surge in Q4

Fierce Pharma

FEBRUARY 21, 2024

In a year that started with more than two-thirds of biopharma companies posting | While Novo Nordisk and Eli Lilly continued to be the biopharma industry growth leaders in the fourth quarter of 2023, many other drugmakers also delivered big gains, including Daiichi Sankyo, Amgen, Teva, GSK and Novartis.

Leads

Leads Biopharma Sales

J.P. Morgan Leads $100M Financing for Startup’s R&D of Covalent Biologic Drugs for Cancer

MedCity News

APRIL 30, 2024

Morgan Leads $100M Financing for Startup’s R&D of Covalent Biologic Drugs for Cancer appeared first on MedCity News. With cancer as its initial focus, the startup contends its approach could offer safety and efficacy advantages compared to currently available targeted therapies. The post J.P.

Leads

Leads Safety Biopharma Pharma

RFK Jr. could 'cost lives in this country' if he pursues changes to US vaccine policy, Gottlieb says

Fierce Pharma

DECEMBER 2, 2024

s appointment last month to lead the U.S. Department of Health and Human Services immediately sent waves of speculation swirling throughout the biopharma industry. | Kennedy Jr.’s The former FDA Commissioner pointed to the threat of measles if vaccination rates were to decline by 5%.

Biopharma

Biopharma FDA Leads

Novo Nordisk, Eli Lilly's obesity drugs will lead in new drug sales in 2024: Evaluate

Fierce Pharma

JANUARY 3, 2024

Booming demand for blood sugar-modulating diabetes and obesity drugs became the top trend in the biopharma industry in 2023, with two companies—Novo Nordisk and Eli Lilly—overwhelming the market wi | Booming demand for blood sugar-modulating diabetes and obesity drugs became the top trend in the biopharma industry in 2023, with two companies—Novo Nordisk (..)

Sales

Sales Biopharma Leads Marketing

With 36% increase, Eli Lilly leads industrywide sales boom in Q2

Fierce Pharma

AUGUST 22, 2024

Once again, fueled by booming sales of their GLP-1 products, Eli Lilly and Novo Nordisk were the top performers in the biopharma industry in the second quarter. |

Sales

Sales Leads Biopharma

FTC Seeks More Information on the $16.5B Novo-Catalent Deal, Leading to Another Delay

MedCity News

MAY 6, 2024

Novo-Catalent Deal, Leading to Another Delay appeared first on MedCity News. Just weeks after Novo decided to resubmit its application to the FTC, the agency is seeking more information about the deal. This move has triggered a second 30-day delay in the antitrust review process. The post FTC Seeks More Information on the $16.5B

Leads

Leads Management Biopharma Pharma

Fat-shedding pill’s data lead to a $132M funding round for startup Rivus Pharma

MedCity News

SEPTEMBER 23, 2022

Rivus Pharmaceuticals’ Series B round will finance ongoing clinical development of its lead drug, a pill that targets mitochondria to increase caloric expenditure.

Leads

Leads Pharma Pharmaceutical Biopharma

AbbVie Gets Another Ulcerative Colitis Contender via $137M Landos Acquisition

MedCity News

MARCH 25, 2024

AbbVie is acquiring Landos Biopharma, whose lead drug is a small molecule that takes a novel approach to treating ulcerative colitis. Preliminary proof-of-concept data from a Phase 2 study are expected later this year.

Biopharma

Biopharma Leads Pharma

Terns Pharma Oral GLP-1 Drug Leads to Greater Than 5% Weight Loss in Small Study

MedCity News

SEPTEMBER 9, 2024

The post Terns Pharma Oral GLP-1 Drug Leads to Greater Than 5% Weight Loss in Small Study appeared first on MedCity News. Terns is one of several companies developing oral GLP-1 obesity medications that could become alternatives to currently available injectable products from this drug class.

Leads

Leads Pharma Pharmaceutical Medical

FogPharma’s $178M Funding Leads Way as 7 Biotechs Raise Cash for Cancer Drugs

MedCity News

NOVEMBER 27, 2022

The biotech’s Series D financing round lays the groundwork to bring its lead program into the clinic in mid-2023, as well as support development of the rest of its pipeline of peptide drugs. FogPharma is preclinical, but not for long.

Leads

Leads Biopharma Pharma

After Data Miss in Lead Cancer Indication, Replimune Maps Path for Oncolytic Virus

MedCity News

DECEMBER 5, 2023

Replimune’s lead therapeutic candidate did not meet the two main goals of a study intended to support an FDA submission in cutaneous squamous cell carcinoma. But Replimune’s therapy, an oncolytic virus, has better data in melanoma, and the company plans a 2024 FDA submission in this skin cancer.

Leads

Leads FDA Biopharma Pharma

M&A Monday: AstraZeneca Leads Way as Three Pharmas Splash Out $3.5B in Deals

MedCity News

JANUARY 9, 2023

billion to acquire CinCor Pharma, a clinical-stage biotech whose lead drug candidate has the potential to treat hypertension in a new way. AstraZeneca has committed $1.3 In other M&A news, Ipsen and Chiesi Farmaceutici each announced acquisitions of rare disease biotechs. All three deals come with contingent value rights.

Leads

Leads Pharma Biopharma

Theseus Pharma Lays Off Staff, Explores Options Months After Toxicity Scuttles Lead Drug

MedCity News

NOVEMBER 14, 2023

Theseus Pharmaceuticals discontinued its former lead program in July following the report of dose-limiting toxicities in two patients. Though Theseus has other assets in its pipeline, it has decided to explore strategic alternatives with the goal of “maximizing shareholder value.”

Leads

Leads Pharma Pharmaceutical Patients

GSK Multiple Myeloma Drug’s DREAMM Comeback Continues With Phase 3 Data at ASH

MedCity News

DECEMBER 9, 2024

The data, presented Monday during the annual meeting of the American Society of Hematology, are part of a submission now under FDA review that could lead to Blenreps return to the market. The post GSK Multiple Myeloma Drugs DREAMM Comeback Continues With Phase 3 Data at ASH appeared first on MedCity News.

FDA

FDA Leads Marketing Patients

Current Lack of Innovation in the Pain Space Hurts Society

MedCity News

DECEMBER 22, 2022

The future towards the safer treatment of pain will come as biopharma, and investor communities appreciate the significant opportunities in supporting scientifically rigorous and clinically validated lead assets for the safer treatment of pain.

Biopharma

Biopharma Leads

Novo Nordisk Commits $285M to Ascendis to Kick Off Alliance on Longer-Acting GLP-1 Drugs

MedCity News

NOVEMBER 4, 2024

The Novo Nordisk/Ascendis partnership’s lead program is once-monthly injectable semaglutide for type 2 diabetes and obesity. This product candidate will be developed with Ascendis Pharma technology that has already yielded two FDA-approved products with longer dosing intervals.

Pharma

Pharma FDA Leads Biopharma

Gut Punch: Finch’s Flagging Microbiome Program Folds, Leading to 95% Staff Cut

MedCity News

JANUARY 24, 2023

Clinical trial setbacks and financial challenges have led Finch Therapeutics to stop a Phase 3 study for its lead microbiome program, a potential treatment for recurrent C. diff infection. As Finch seeks buyers for its remaining assets, the biotech is laying off most of its staff in a corporate restructuring.

Leads

Leads Biopharma Pharma

After Merck's flashpoint IRA lawsuit, Biogen CEO and others register their own complaints

Fierce Pharma

JUNE 7, 2023

Merck has taken the lead, filing a lawsuit seeking to overturn drug pricing measures in the Inflation Reduction Act (IRA). Now, emboldened by the New Jersey drugmaker, other biopharma CEOs are making their concerns known. Merck has filed a lawsuit seeking to overturn drug-pricing measures in the Inflation Reduction Act (IRA).

Biopharma

Biopharma Leads

Akero’s New MASH Drug Data: Longer Treatment Leads to More Liver Benefit

MedCity News

MARCH 4, 2024

Akero Therapeutics’ preliminary Phase 2b data show that treatment with its MASH drug, efruxifermin, continued to distance itself from a placebo measured at nearly two years of treatment. The latest Akero data build on six-month results reported in 2022.

Leads

Leads Biopharma Pharma

FDA Reconsideration Leads to Approval of Takeda Drug for Rare Esophagus Disorder

MedCity News

FEBRUARY 12, 2024

FDA approval of Takeda Pharmaceutical drug Eohilia introduces a new therapeutic option for patients with eosinophilic esophagitis, inflammation of the esophagus that causes swallowing difficulty. It will compete against Dupixent, a Sanofi and Regeneron Pharmaceuticals drug already approved for this disorder.

FDA

FDA Leads Pharmaceutical Patients

Eikon Raises $350M for Cancer Drug Pipeline Led by Melanoma Med in Pivotal Testing

MedCity News

FEBRUARY 26, 2025

Eikon Therapeutics lead drug candidate is designed to activate toll-like receptors 7 and 8, sparking an immune response that fights cancer. Beyond this TLR7/8 agonist, the biotech is also developing PARP inhibitors that could have advantages over cancer drugs currently available from this class.

Leads

Leads Biopharma Pharma

RNAi Biotech Atalanta Unveils $97M to Reach the Clinic in Two Rare Neuro Diseases

MedCity News

JANUARY 28, 2025

Lead programs for Huntingtons disease and a rare inherited form epilepsy are on track to enter the clinic this year. The structure of Atalanta Therapeutics RNA interference drugs enables them to distribute broadly and deeply into brain tissue.

Distribution

Distribution Leads Biopharma Pharma

FDA setback leads women’s health biotech ObsEva to give up on uterine fibroids drug

MedCity News

JULY 27, 2022

ObsEva’s uterine fibroids drug linzagolix has hit a snag at the FDA, portending a likely delayed regulatory decision. Rather than stick it out and see if its small molecule can match up against commercialized products from AbbVie and Myovant, ObsEva plans to give up rights to the drug as part of a corporate restructuring.

FDA

FDA Leads Biopharma Pharma

Ascentage Has First U.S. Biotech IPO of 2025, Raising $126M to Bring Its Cancer Meds to the World

MedCity News

JANUARY 24, 2025

IPO will support clinical testing of its two lead drugs, small molecules in development for advanced cases of certain blood cancers. Ascentage Pharmas U.S. Takeda holds an exclusive option to develop and commercialize one of those drugs in most of the world. The post Ascentage Has First U.S.

Pharma

Pharma Leads Biopharma

New Hemophilia Data Lead FDA to Delay Decision for BioMarin Gene Therapy

MedCity News

MARCH 7, 2023

BioMarin Pharmaceutical’s submission of additional data for patients treated with its hemophilia A gene therapy, Roctavian, mean that the FDA will push out a regulatory decision to early summer. But it could be worth the wait as analysts anticipate FDA approval and project Roctavian becoming one of BioMarin’s biggest products.

FDA

FDA Leads Pharmaceutical Patients

Cardiac Complication Leads FDA to Place Foghorn Cancer Drug Under Partial Hold

MedCity News

APRIL 24, 2023

A clinical trial for a Foghorn Therapeutics cancer drug is under a partial FDA hold after a patient in the early-stage study developed a cardiovascular complication. It’s the biotech’s second partial hold in the past year.

FDA

FDA Leads Patients Biopharma

‘Challenging Market’ Leads MorphoSys to Cut Preclinical R&D, Turn Focus to Cancer

MedCity News

MARCH 2, 2023

MorphoSys’s emphasis on its clinical-stage cancer programs puts the spotlight on a myelofibrosis drug candidate from its 2021 acquisition of Constellation Pharmaceuticals. That small molecule could compete against drug candidates from GSK and Merck.

Leads

Leads Marketing Pharmaceutical Biopharma

Leading Clinical Trial Recruitment Strategies Center Around Real-World Data

MedCity News

JANUARY 3, 2023

By allowing study teams to design and conduct more inclusive and/or relevant studies, real-world data can enhance the standard of care and ultimately improve patient outcomes.

Recruitment

Recruitment Leads Patients Biopharma

Adverse Survival Signal Leads G1 to Stop Pivotal Test in Colorectal Cancer

MedCity News

FEBRUARY 13, 2023

G1 Therapeutics said its drug met the main goal of a Phase 3 study in colorectal cancer, but the preliminary results also show measures of survival are better in the placebo arm. The company is stopping the colorectal cancer study.

Leads

Leads Biopharma Pharma

Safety Risks and FDA Hold Lead Gilead to Stop Work on Drug in Blood Cancers

MedCity News

FEBRUARY 7, 2024

Gilead Sciences said an independent review of interim Phase 3 data found the immunotherapy, magrolimab, led to a higher risk of death. Though Gilead is discontinuing further development of the drug in blood cancers, a review is ongoing in solid tumors.

Safety

Safety Leads FDA Biopharma

RA Capital Leads $150M Financing for Septerna and Lead Drug With Oral Edge in Rare Hormone Disease

MedCity News

JULY 11, 2023

Septerna Therapeutics’ Series B financing will support plans to reach the clinic with a pill for a rare disease whose only approved therapy is a Takeda Pharmaceutical drug that’s leaving the market. Potential rival therapies are all injectables.

Leads

Leads Pharmaceutical Marketing Biopharma

A Father’s Vision for New Kind of Gene Therapy Leads to a $100M Financing

MedCity News

MAY 29, 2023

Ray Therapeutics’ gene therapy is independent of the causative genes driving inherited vision disorders, which CEO Paul Bresge says is important for reaching a broad patient population. Rare disease retinitis pigmentosa is the first disease target, but the startup also plans to test its approach in more prevalent eye disorders.

Leads

Leads Patients Biopharma Pharma

Amylyx ALS drug’s winding regulatory path leads to long-awaited FDA approval

MedCity News

SEPTEMBER 30, 2022

An Amylyx Pharmaceuticals drug developed to slow the progression of amyotrophic lateral sclerosis is now approved, making it just the third FDA-approved treatment for the disease. Amylyx will market its new product under the name “Relyvrio.”.

FDA

FDA Leads Pharmaceutical Marketing

Novo Nordisk Follows Eli Lilly’s Lead, Lowering Insulin Prices up to 75%

MedCity News

MARCH 14, 2023

Novo Nordisk can afford the price cuts prices to several branded and non-branded insulins. Flattening revenue for the pharmaceutical giant’s insulin products is offset by demand for diabetes and obesity drugs from its semaglutide franchise, which continues to grow by leaps and bounds.

Leads

Leads Pharmaceutical Biopharma Pharma

Acelyrin’s $300M haul for novel biologic leads a slate of biotech financings

MedCity News

SEPTEMBER 18, 2022

The biggest biotech financing of the past week belongs to a startup developing an immunology drug that could rival blockbuster products sold by big pharmaceutical companies. Cell therapy, cancer, and rare disease also figured into this week’s startup cash hauls.

Leads

Leads Pharmaceutical Biopharma Pharma

Aardvark Therapeutics’ Pursuit of New Obesity Target Adds $94M in IPO Cash

MedCity News

FEBRUARY 13, 2025

The biotechs lead drug candidate is in Phase 3 testing in Prader-Willi syndrome, a genetic disorder that causes persistent hunger leading to overeating. GLP-1 drugs dominate the obesity market, but Aardvark Therapeutics aims to curb appetite by going after a different target: TAS2 receptors in the gut.

Leads

Leads Marketing Biopharma Pharma

Automation to accelerate biopharma in next decade

European Pharmaceutical Review

APRIL 17, 2023

A report on automation in the biopharma industr y has shown that the market is projected to grow at a compound annual growth rate (CAGR) of 5.7 Factors impacting the automation in the biopharma industry market The report found that 75 percent of pharmaceutical organisations want to use automated solutions more frequently.

Biopharma

Biopharma Manufacturing Pharmaceutical products Marketing

Safety Risk Sinks Cargo Therapeutics’ Cancer Cell Therapy Prospect, Leading to 50% Staff Cut

Eli Lilly’s Zepbound Leads to Greater Weight Loss vs. Novo Nordisk Drug in Head-to-Head Test

Trending Sources

Going In Reverse Is Faster Way Forward for Crescent Bio’s Cancer Immunotherapy

Rare Metabolic Disease That Leads to Childhood Obesity Gets Its First FDA-Approved Drug

3 Reasons Why The Biopharma M&A Market Is Ready For Takeoff

Disappointing data lead Pfizer to drop heart drug acquired as part of $11B deal

An ocean of answers in a single cell — how proteomics can lead to better drugs

Novo Nordisk, Eli Lilly lead industrywide sales surge in Q4

J.P. Morgan Leads $100M Financing for Startup’s R&D of Covalent Biologic Drugs for Cancer

RFK Jr. could 'cost lives in this country' if he pursues changes to US vaccine policy, Gottlieb says

Novo Nordisk, Eli Lilly's obesity drugs will lead in new drug sales in 2024: Evaluate

With 36% increase, Eli Lilly leads industrywide sales boom in Q2

FTC Seeks More Information on the $16.5B Novo-Catalent Deal, Leading to Another Delay

Fat-shedding pill’s data lead to a $132M funding round for startup Rivus Pharma

AbbVie Gets Another Ulcerative Colitis Contender via $137M Landos Acquisition

Terns Pharma Oral GLP-1 Drug Leads to Greater Than 5% Weight Loss in Small Study

FogPharma’s $178M Funding Leads Way as 7 Biotechs Raise Cash for Cancer Drugs

After Data Miss in Lead Cancer Indication, Replimune Maps Path for Oncolytic Virus

M&A Monday: AstraZeneca Leads Way as Three Pharmas Splash Out $3.5B in Deals

Theseus Pharma Lays Off Staff, Explores Options Months After Toxicity Scuttles Lead Drug

GSK Multiple Myeloma Drug’s DREAMM Comeback Continues With Phase 3 Data at ASH

Current Lack of Innovation in the Pain Space Hurts Society

Novo Nordisk Commits $285M to Ascendis to Kick Off Alliance on Longer-Acting GLP-1 Drugs

Gut Punch: Finch’s Flagging Microbiome Program Folds, Leading to 95% Staff Cut

After Merck's flashpoint IRA lawsuit, Biogen CEO and others register their own complaints

Akero’s New MASH Drug Data: Longer Treatment Leads to More Liver Benefit

FDA Reconsideration Leads to Approval of Takeda Drug for Rare Esophagus Disorder

Eikon Raises $350M for Cancer Drug Pipeline Led by Melanoma Med in Pivotal Testing

RNAi Biotech Atalanta Unveils $97M to Reach the Clinic in Two Rare Neuro Diseases

FDA setback leads women’s health biotech ObsEva to give up on uterine fibroids drug

Ascentage Has First U.S. Biotech IPO of 2025, Raising $126M to Bring Its Cancer Meds to the World

New Hemophilia Data Lead FDA to Delay Decision for BioMarin Gene Therapy

Cardiac Complication Leads FDA to Place Foghorn Cancer Drug Under Partial Hold

‘Challenging Market’ Leads MorphoSys to Cut Preclinical R&D, Turn Focus to Cancer

Leading Clinical Trial Recruitment Strategies Center Around Real-World Data

Adverse Survival Signal Leads G1 to Stop Pivotal Test in Colorectal Cancer

Safety Risks and FDA Hold Lead Gilead to Stop Work on Drug in Blood Cancers

RA Capital Leads $150M Financing for Septerna and Lead Drug With Oral Edge in Rare Hormone Disease

A Father’s Vision for New Kind of Gene Therapy Leads to a $100M Financing

Amylyx ALS drug’s winding regulatory path leads to long-awaited FDA approval

Novo Nordisk Follows Eli Lilly’s Lead, Lowering Insulin Prices up to 75%

Acelyrin’s $300M haul for novel biologic leads a slate of biotech financings

Aardvark Therapeutics’ Pursuit of New Obesity Target Adds $94M in IPO Cash

Automation to accelerate biopharma in next decade

Stay Connected